Home / Innere Medizin / Onkologie / Alexander Eggermont presents the results of KEYNOTE-054

Alexander Eggermont presents the results of KEYNOTE-054

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab’s high therapeutic index.

Reference:
Eggermont AMM et al., abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 053 double-blinded phase III trial

LOGIN

Login

Passwort vergessen?